Acts on spinal reflex pathways and reduces reflex-mediated skeletal-muscle tone. Experimental work supports depression of spinal reflex activity and effects on voltage-gated sodium/calcium channels; a 2024 study also reported P2X7 antagonism, but the established clinical mechanism remains incompletely elucidated.
Indications / reported uses
Improvement of myotonic conditions associated with neck-shoulder-arm syndrome, scapulohumeral periarthritis and low back pain
Spastic paralysis associated with selected cerebrovascular, spinal and other neurological disorders in the cited Japanese product information; authorisation varies by country
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
ERA assessment scope
Project-specific environmental risk assessment support
The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.
Phase I exposure screening and trigger evaluation.
Environmental fate and ecotoxicity review, with Phase II work where required.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope
Environmental Risk Assessment (ERA)
ReguSight provides project-specific support for the Eperisone Environmental Risk Assessment (ERA) (the Eperisone ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.
Assessment may cover
Product, active-substance identity, formulation, route and intended-market review.
Phase I environmental exposure screening and applicable trigger evaluation.
Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
Data-gap analysis, study strategy, assumptions and scientific reporting.
The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.